Alzheimer's prevention initiative: A plan to accelerate the evaluation of presymptomatic treatments

Advances in Alzheimer's Disease

Volumn 2, Issue , 2011, Pages 589-597

  Reiman, Eric M ^a,b,c,d   Langbaum, Jessica B S ^a,d   Fleisher, Adam S ^a,d,e,f   Caselli, Richard J ^d,g   Chen, Kewei ^a,d,h   Ayutyanont, Napatkamon ^a,d   Quiroz, Yakeel T ⁱ   Kosik, Kenneth S ^j   Lopera, Francisco ^k   Tariot, Pierre N ^a,b,d,f  

^a BANNER ALZHEIMER S INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d ARIZONA ALZHEIMER S CONSORTIUM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Alzheimers Disease Cooperative Study (ADCS)   (United States)

^g MAYO CLINIC   (United States)

^h ARIZONA STATE UNIVERSITY   (United States)

ⁱ BOSTON UNIVERSITY   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSIDAD DE ANTIOQUIA   (Colombia)

more..

Author keywords

apolipoprotein E; biomarkers; Brain imaging; cerebral spinal fluid; clinical trials; early onset Alzheimer's disease; late onset Alzheimer's disease; presenilin 1; presymptomatic Alzheimer's disease; surrogate markers

Indexed keywords

ALZHEIMER DISEASE; ALZHEIMER PREVENTION INITIATIVE; ARTICLE; ASYMPTOMATIC DISEASE; BRAIN RADIOGRAPHY; CEREBROSPINAL FLUID ANALYSIS; HUMAN; IMAGE ANALYSIS; NEUROIMAGING; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROPHYLAXIS; RISK ASSESSMENT;

EID: 84865436076     PISSN: 22105727     EISSN: 22105735     Source Type: Book Series    
DOI: 10.3233/978-1-60750-793-2-589     Document Type: Article

References (86)

1. Reiman EM, Langbaum JBS, Tariot PN (2010) Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med 4, 3-14.
2. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging and the Alzheimer's associationworkgroup. Alzheimers Dement 7, 280-292.
3. Alzheimer's Association (2011) Alzheimer's disease facts and figures. Alzheimers Dement 7, 208-244
4. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342.
5. Lautenschlager NT, Cox KL, Flicker L, Foster JK, van Bockxmeer FM, Xiao J, Greenop KR, Almeida OP (2008) Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 300, 1027-1037.
6. Wang HX, Karp A, Winblad B, Fratiglioni L (2002) Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am J Epidemiol 155, 1081-1087.
7. Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y (2009) Physical activity, diet, and risk of Alzheimer disease. JAMA 302, 627-637.
8. Haag MDM, Hofman A, Koudstaal PJ, Stricker BHC, Breteler MMB (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80, 13-17.
9. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ (2006) Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 37, 1165-1170.
10. Szekely CA, Green RC, Breitner JCS, Ostbye T, Beiser AS, Corrada MM, Dodge HH, Ganguli M, Kawas CH, Kuller LH, Psaty BM, Resnick SM, Wolf PA, Zonderman AB, Welsh-Bohmer KA, Zandi PP (2008) No advantage of A 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70, 2291-2298.
11. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the cache county study. Arch Neurol 61, 82-88.
12. Ball K, Berch DB, Helmers KF, Jobe JB, Leveck MD, Marsiske M, Morris JN, Rebok GW, Smith DM, Tennstedt SL, Unverzagt FW, Willis SL (2002) Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA 288, 2271-2281.
13. Kramp VP, Herrling P (2011) List of drugs in development for neurodegenerative diseases: update June 2010. Neurodegener Dis 8, 44-94.
14. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
15. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD (2008) For the ginkgo evaluation of memory (GEM) study investigators, Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300, 2253-2262.
16. ADAPT Research Group (2008) Cognitive function over time in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65, 896-905.
17. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, III, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the women's health initiative memory study: a randomized controlled trial. JAMA 289, 2651-2662.
18. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausalwomen: women's health initiative memory study. JAMA 291, 2947-2958.
19. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the ?4 allele for apolipoprotein E. N Engl J Med 334, 752-758.
20. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J (2001) Declining brain activity in cognitively normal apolipoprotein E ?4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 98, 3334-3339.
21. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 101, 284-289.
22. Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J (2005) Correlations between apolipoprotein E ?4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA 102, 8299-8302.
23. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JBS, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ (2009) Fibrillar amyloid-burden in cognitively normal people at three levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 106, 6820-6825.
24. Reiman EM, Langbaum JBS (2009) Brain imaging in the evaluation of putative Alzheimer's disease slowing, risk-reducing and prevention therapies. In: Imaging the Aging Brain. Jagust WJ, D'Esposito M (Eds.). Oxford University Press, New York, pp. 319-350.
25. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, Rossor MN (1996) Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 119, 2001-2007.
26. Mosconi L, Sorbi S, de Leon MJ, Li Y, Nacmias B, Myoung PS, Tsui W, Ginestroni A, Bessi V, Fayyazz M, Caffarra P, Pupi A (2006) Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 47, 1778-1786.
27. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW (2000) Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 343, 450-456.
28. Burggren AC, Zeineh MM, Ekstrom AD, Braskie MN, Thompson PM, Small GW, Bookheimer SY (2008) Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E ?4 carriers. Neuroimage 41, 1177-1183.
29. Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, Kaplan A, La Rue A, Adamson CF, Chang L (1995) Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273, 942-947.
30. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, Lavretsky H, Miller K, Siddarth P, Rasgon NL, Mazziotta JC, Saxena S, Wu HM, Mega MS, Cummings JL, Saunders AM, Pericak-Vance MA, Roses AD, Barrio JR, Phelps ME (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 97, 6037-6042.
31. Small GW, Komo S, La RA, Saxena S, Phelps ME, Mazziotta JC, Saunders AM, Haines JL, Pericak-Vance MA, Roses AD (1996) Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann N Y Acad Sci 802, 70-78.
32. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, 343-349.
33. Johnson KA, Lopera F, Jones K, Becker A, Sperling R, Hilson J, Londono J, Siegert I, Arcos M, Moreno S, Madrigal L, Ossa J, Pineda N, Ardila A, Roselli M, Albert MS, Kosik KS, Rios A (2001) Presenilin-1-associated abnormalities in regional cerebral perfusion. Neurology 56, 1545-1551.
34. Valla J, Yaari R, Wolf AB, Kusne Y, Beach TG, Roher AE, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM (2010) Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis 22, 307-313.
35. Beckett LA, Harvey DJ, Gamst A, Donohue M, Kornak J, Zhang H, Kuo JH (2010) The Alzheimer's Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement 6, 257-264.
36. Chen K, Langbaum JBS, Fleisher AS, Ayutyanont N, Reschke C, Lee W, Liu X, Bandy D, Alexander GE, Thompson PM, Foster NL, Harvey DJ, de Leon MJ, Koeppe RA, Jagust WJ, Weiner MW, Reiman EM (2010) The Alzheimer's Disease Neuroimaging, Initiative Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's disease neuroimaging initiative. Neuroimage 51, 654-664.
37. Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8, 431-440.
38. Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125, 605-613.
39. Biomarkers Definitions Working, Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69, 89-95.
40. Katz R (2004) Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1, 189-195.
41. Broich K (2007) Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective. Int Psychogeriatr 19, 509-524.
42. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
43. Langbaum JB, Chen K, Caselli RJ, Lee W, Reschke C, Bandy D, Alexander GE, Burns CM, Kaszniak AW, Reeder SA, Corneveaux JJ, Allen AN, Pruzin J, Huentelman MJ, Fleisher AS, Reiman EM (2010) Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. Arch Neurol 67, 462-468.
44. Reiman EM, Caselli RJ, Alexander GE, Chen K (2001) Tracking the decline in cerebral glucose metablolism in persons and laboratory animals at genetic risk for Alzheimer's disease. Clin Neurosci Res 1, 194-206.
45. Chen K, Reiman EM, Alexander GE, Caselli RJ, Bandy D (2006) Using partial-least squares to demonstrate a correlation between combined PET/MRI scores and apolipoprotein E ?4 gene dose. Alzheimers Dement 2, S672-S673
46. Chen K, Reiman EM, Huan Z, Caselli RJ, Bandy D, Ayutyanont N, Alexander GE (2009) Linking functional and structural brain images with multivariate network analyses: A novel application of the partial least square method. Neuroimage 47, 602-610.
47. Corneveaux JJ, Liang WS, Reiman EM, Webster JA, Myers AJ, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Craig DW, Coon KD, Dunckley T, Bandy D, Lee W, Chen K, Beach TG, Mastroeni D, Grover A, Ravid R, Sando SB, Aasly JO, Heun R, Jessen F, Kolsch H, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Papassotiropoulos A, Stephan DA, Huentelman MJ (2010) Evidence for an association between KIBRA and late-onset Alzheimer's disease. Neurobiol Aging 31, 901-909.
48. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon KD, Liang WS, Herbert RH, Beach T, Rohrer KC, Zhao AS, Leung D, Bryden L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Heward CB, Ravid R, Rogers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Kukull W, Papassotiropoulos A, Stephan DA (2007) GAB2 alleles modify Alzheimer's risk in APOE ?4 carriers. Neuron 54, 713-720.
49. Liang WS, Chen K, Lee W, Sidhar K, Corneveaux JJ, Allen AN, Myers A, Villa S, Meechoovet B, Pruzin J, Bandy D, Fleisher AS, Langbaum JB, Huentelman MJ, Jensen K, Dunckley T, Caselli RJ, Kaib S, Reiman EM (2011) Association betweenGAB2haplotype and higher glucose metabolism in Alzheimer's disease-affected brain regions in cognitively normal APOEepsilon4 carriers. Neuroimage 54, 1896-1902.
50. Reiman EM, Chen K, Caselli RJ, Alexander GE, Bandy D, Adamson JL, Lee W, Cannon A, Stephan EA, Stephan DA, Papassotiropoulos A (2008) Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer'saffected brain regions. Neuroimage 40, 1214-1221.
51. Reiman EM, Chen K, Langbaum JB, Lee W, Reschke C, Bandy D, Alexander GE, Caselli RJ (2010) Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. Neuroimage 49, 169-176.
52. Alexander GE, Chen K, Reiman EM, Caselli RJ, Lewis D, Bandy D, Prouty A (2002) Longitudinal declines of gray matter in cognitively normal apolipoprotein E ?4 homozygotes and heterozygotes evaluated by voxel-based MRI morphometry. Neurobiol Aging 23, s363.
53. Chen K, Reiman EM, Alexander GE, Caselli RJ, Gerkin R, Bandy D, Domb A, Osborne D, Fox N, Crum WR, Saunders AM, Hardy J (2007) Correlations between apolipoprotein E ?4 gene dose and whole brain atrophy rates. Am. J Psychiatry 164, 916-921.
54. Chen K, Reiman EM, Alexander GE, Bandy D, Renaut R, Crum WR, Fox NC, Rossor MN (2004) An automated algorithm for the computation of brain volume change from sequential MRIs using an iterative principal component analysis and its evaluation for the assessment of whole-brain atrophy rates in patients with probable Alzheimer's disease. Neuroimage 22, 134-143.
55. Caselli RJ, Hentz JG, Osborne D, Snyder CH, Alexander GE, Reiman EM (2006) Presymptomatic longitudinal decline in frontally mediated cognitive skills and memory in cognitively normal late middle aged APOE ?4 carriers. Alzheimers Dement 2, S292.
56. Caselli RJ, Reiman EM, Osborne D, Hentz JG, Baxter LC, Hernandez JL, Alexander GG (2004) Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE ?4 allele. Neurology 62, 1990-1995.
57. Caselli RJ, Osborne D, Reiman EM, Hentz JG, Barbieri CJ, Saunders AM, Hardy J, Graff-Radford NR, Hall GR, Alexander GE (2001) Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-4/4 homozygotes: a replication study. J Neurol Sci 189, 93-98.
58. Caselli RJ, Graff-Radford NR, Reiman EM, Weaver A, Osborne D, Lucas J, Uecker A, Thibodeau SN (1999) Preclinical memory decline in cognitively normal apolipoprotein E-4 homozygotes. Neurology 53, 201-207.
59. Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, Woodruff BK, Alexander GE, Osborne D (2007) Cognitive domain decline in healthy Apolipoprotein E ?4 homozygotes before the diagnosis of Mild Cognitive Impairment. Arch Neurol 64, 1306-1311.
60. Caselli RJ, Chen K, Lee W, Alexander GE, Reiman EM (2008) Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch Neurol 65, 1231-1236.
61. Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, Baxter LC, Rapcsak SZ, Shi J, Woodruff BK, Locke DEC, Hoffman-Snyder C, Alexander GE, Rademakers R, Reiman EM (2009) Longitudinal modeling of age-related memory decline and the APOE 4 effect. N Engl J Med 361, 255-263.
62. Caselli RJ, Dueck AC, Locke DE, Sabbagh MN, Ahern GL, Rapcsak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM (2011) Cerebrovascular risk factors and preclinical memory decline in healthy APOE 4 homozgyotes. Neurology 76, 1078-1084.
63. Chen K, Ayutyanont N, Langbaum JBS, Fleisher AS, Reschke C, Lee W, Liu X, Bandy D, Alexander GE, Thompson PM, Shaw L, Trojanowski JQ, Jack CR Jr, Landau SM, Foster NL, Harvey DJ, Weiner MW, Koeppe RA, Jagust WJ, Reiman EM (2011) Alzheimer's Disease Neuroimaging Initiative. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 56, 52-60.
64. Klunk WE, Mathis CA, Price JC, Lopresti BJ, DeKosky ST (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 2805-2807.
65. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C (2011) Autosomal-dominant Alzheimer's disease: a reviewand proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther 3, 1.
66. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B (2011) Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76, 280-286.
67. Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JCS, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ (2010) Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement 6, 89-97.
68. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM, Jaramillo-Elorza MC, Moreno S, Aguirre-Acevedo DC, Saldarriaga A, Lopera F (2011) Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol 10, 213-220.
69. Arango-Lasprilla JC, Cuetos F, Valencia C, Uribe C, Lopera F (2007) Cognitive changes in the preclinical phase of familial Alzheimer's disease. J Clin Exp Neuropsychol 29, 892-900.
70. Arango Lasprilla JC, Iglesias J, Lopera F (2003) Neuropsychological study of familial Alzheimer's disease caused by mutation E280A in the presenilin 1 gene. Am J Alzheimers Dis Other Demen 18, 137-146.
71. Ardila A, Lopera F, Rosselli M, Moreno S, Madrigal L, Arango-Lasprilla JC, Arcos M, Murcia C, Arango-Viana JC, Ossa J, Goate A, Kosik KS (2000) Neuropsychological profile of a large kindred with familial Alzheimer's disease caused by the E280A single presenilin-1 mutation. Arch Clin Neuropsychol 15, 515-528.
72. Lopera F, Ardilla A, Martinez A, Madrigal L, Arango-Viana JC, Lemere CA, Arango-Lasprilla JC, Hincapie L, Arcos-Burgos M, Ossa JE, Behrens IM, Norton J, Lendon C, Goate AM, Ruiz-Linares A, Rosselli M, Kosik KS (1997) Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 277, 793-799.
73. Rosselli MC, Ardila AC, Moreno SC, Standish VC, Arango-Lasprilla JC, Tirado VM, Ossa JM, Goate AM, Kosik KS, Lopera F (2000) Cognitive decline in patients with familial Alzheimer's disease associated with E280a presenilin-1 mutation: a longitudinal study. J Clin Exp Neuropsychol 22, 483-495.
74. Quiroz YT, Budson AE, Celone K, Ruiz A, Newmark R, Castrillon G, Lopera F, Stern CE (2010) Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann Neurol 68, 865-875.
75. Bobes MA, Garcia YF, Lopera F, Quiroz YT, Galan L, Vega M, Trujillo N, Valdes-Sosa M, Valdes-Sosa P (2010) ERP generator anomalies in presymptomatic carriers of the Alzheimer's disease E280A PS-1 mutation. Hum Brain Mapp 31, 247-265.
76. Cuetos F, Arango-Lasprilla JC, Uribe C, Valencia C, Lopera F (2007) Linguistic changes in verbal expression: a preclinical marker of Alzheimer's disease. J Int Neuropsychol Soc 13, 433-439.
77. Dorfman VB, Pasquini L, Riudavets M, Lopez-Costa JJ, Villegas A, Troncoso JC, Lopera F, Castano EM, Morelli L (2010) Differential cerebral deposition of IDE and NEP in sporadic and familial Alzheimer's disease. Neurobiol Aging 31, 1743-1757.
78. Gomez-Isla T, Growdon WB, McNamara MJ, Nochlin D, Bird TD, Arango JC, Lopera F, Kosik KS, Lantos PL, Cairns NJ, Hyman BT (1999) The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors. Brain 122 (Pt 9), 1709-1719.
79. Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango JC, Anthony DC, Koo EH, Goate AM, Selkoe DJ, Arango JC (1996) The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med 2, 1146-1150.
80. Lendon CL, Martinez A, Behrens IM, Kosik KS, Madrigal L, Norton J, Neuman R, Myers A, Busfield F, Wragg M, Arcos M, Arango Viana JC, Ossa J, Ruiz A, Goate AM, Lopera F (1997) E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. Hum Mutat 10, 186-195.
81. Mejia S, Giraldo M, Pineda D, Ardila A, Lopera F (2003) Nongenetic factors as modifiers of the age of onset of familial Alzheimer's disease. Int Psychogeriatr 15, 337-349.
82. Parra MA, Sala SD, Abrahams S, Logie RH, Mendez LG, Lopera F (2011) Specific deficit of colour-colour shortterm memory binding in sporadic and familial Alzheimer's disease. Neuropsychologia. doi:10.1016/j.neuropsychologia. 2011.03.022
83. Parra MA, Abrahams S, Logie RH, Mendez LG, Lopera F, Della SS (2010) Visual short-term memory binding deficits in familial Alzheimer's disease. Brain 133, 2702-2713.
84. Kosik KS, Lopera F (2008) Genetic testing must recognize impact of bad news on recipient. Nature 454, 158-159.
85. Strobel, G. (2011) Alzheimer's Prevention Intiative: a six part series. Alzheimer Research Forum, http://www.alzforum. org/new/detail.asp?id=2720, Accessed March 15, 2011.
86. Strobel, G. (2010) Phoenix: Vision of shared prevention trials lures pharma to table. Alzheimer Research Forum, http://www.alzforum.org/new/detail. asp?id=2374, Accessed February 25, 2010